PGC as a Biomarker for Barrett’s Esophagus to Esophageal Adenocarcinoma
Author Information
Author(s): Qureshi Sajida, Abbasi Waqas Ahmad, Qureshi Muhammad Asif, Jalil Hira Abdul, Quraishy Muhammad Saeed
Primary Institution: Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Hypothesis
This study investigates the role of PGC expression in the progression from Barrett’s esophagus to esophageal adenocarcinoma.
Conclusion
PGC could serve as a promising biomarker for predicting the high-risk transformation from Barrett’s esophagus to esophageal adenocarcinoma.
Supporting Evidence
- PGC was upregulated in various cancers, especially in adjacent normal tissues of esophageal adenocarcinoma.
- Genomic amplifications of PGC were linked to improved survival in esophageal adenocarcinoma patients.
- PGC expression positively correlated with favorable immune infiltration, notably B cells and CD8+ T cells.
- PGC was identified among the top 10 hub genes in the analysis of downregulated genes.
Takeaway
This study found that a protein called PGC might help doctors know if someone with Barrett's esophagus is at risk of getting a more serious cancer called esophageal adenocarcinoma.
Methodology
The study used multiple bioinformatic platforms to assess PGC expression, genomic alterations, and correlations with clinicopathological features, survival, and immune infiltration.
Potential Biases
Potential biases may arise from the reliance on bioinformatics analyses without experimental validation.
Limitations
The study relies on publicly available datasets, which may not capture the complexities of tumor biology.
Participant Demographics
The study analyzed data from patients with nondysplastic Barrett’s esophagus and those who progressed to malignancy.
Statistical Information
P-Value
0.055
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website